Expanded Fetal Test and Stronger ALTAIR Signal Could Be A Game Changer For Natera (NTRA)

• Natera has recently launched an expanded 21‑gene Fetal Focus single‑gene non‑invasive prenatal test, backed by blinded prospective EXPAND trial data showing high sensitivity and specificity across a wider range of inherited conditions.
• New post‑hoc analysis from the ALTAIR trial, to be presented at the 2026 ASCO GI Symposium, found a statistically significant disease‑free survival benefit for Signatera‑positive colorectal cancer patients treated with Trifluridine/Tipiracil, marking a meaningful upgrade from earlier, non‑significant results.
• We’ll now examine how the stronger ALTAIR disease‑free survival signal could influence Natera’s broader investment narrative and growth expectations.

We've found 14 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Natera Investment Narrative Recap

To own Natera, you need to believe in broad clinical adoption of its molecular tests in oncology and women’s health, with growing reimbursement support offsetting current losses and high investment. The stronger disease free survival signal from ALTAIR and the expanded Fetal Focus panel bolster the clinical story, but do not fundamentally change the key near term catalyst of additional reimbursement and guideline wins, or the biggest risk that expensive trials and commercialization could weigh on margins longer than investors expect.

Among the recent updates, the post hoc ALTAIR analysis is most relevant here, because it turns an earlier non significant disease free survival trend into a statistically significant benefit for Signatera positive colorectal cancer patients treated with Trifluridine/Tipiracil. That kind of outcome data could feed into future reimbursement and guideline discussions, directly tied to Natera’s central catalyst of turning heavy R&D and SG&A spending into more durable, higher quality oncology revenue rather than just volume driven growth.

Yet even with stronger ALTAIR data, investors should still be aware that high and growing R&D and SG&A spend could...

Read the full narrative on Natera (it's free!)

Natera's narrative projects $3.0 billion revenue and $110.9 million earnings by 2028.

Uncover how Natera's forecasts yield a $234.68 fair value, in line with its current price.

Exploring Other Perspectives

Eight fair value estimates from the Simply Wall St Community span roughly US$65 to US$285 per share, showing how far apart individual views can be. When you weigh that spread against Natera’s continued dependence on successful clinical trials and future reimbursement decisions, it becomes clear why many readers choose to compare several perspectives before forming a view on the stock’s long term potential.

Explore 8 other fair value estimates on Natera - why the stock might be worth less than half the current price!

Build Your Own Natera Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Natera research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Natera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Natera's overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find companies with promising cash flow potential yet trading below their fair value.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 38 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com